3. (Amended) A dosage form of Claim 2 wherein the glitazone is troglitazone and the polymer is hydroxypropyl cellulose at a weight ratio of 75:25 respectively.

Please add the following new claims:

8. (Newly added) A dosage form of Claim 1 wherein said matrix further comprises a solubilizer.

9. (Newly added) The dosage form of Claim 8 wherein said solubilizer comprises polyethylene glycol.

10. (Newly added) The dosage form of Claim 1 wherein said dosage form comprises 75% by weight of said pharmaceutical agent.

11. (Newly added) A process for the preparation of a solid particulate dosage form of a sparingly water-soluble pharmaceutical agent comprising:

a) blending the pharmaceutical agent in particulate form with a water-soluble polymer;

b) mixing the blend at a temperature at which the polymer at least softens and the pharmaceutical agent remains crystalline in order to coat the particulate with a matrix comprising said polymer;

c) extruding the mix through an extruder and allowing the extrudate to cool to solidify said matrix;

d) milling the extrudate into a powdery mass;

e) blending the solid particulate with an excipient; and

f) shaping the blended solid particulate into the solid dosage form.

12. (Newly added) The process of Claim 11 wherein said polymer is selected from the group consisting of hydroxypropyl cellulose, hydroxypropyl methylcellulose, polyvinyl pyrrolidone, polyethylene-oxides, pregelatinized starch, methylcellulose, hydroxyethylcellulose, polyvinyl alcohol, sodium alginate, sodium carboxymethylcellulose, lecithin, tweens, maltodextrin, poloxamer, sodium laurylsulfate, vinyl acetate copolymer, Eudragit® acrylic polymers, E-100, and mixtures thereof.

13. (Newly added) The process of Claim 12 wherein the polymer is hydroxypropyl cellulose or hydroxypropyl methylcellulose.

14. (Newly added) The process of Claim 13 wherein the polymer is hydroxypropyl cellulose.

15. (Newly added) The process of Claim 13 wherein the polymer is hydroxypropyl methylcellulose.

16. (Newly added) The process of Claim 11 wherein the first blending step further comprises blending a solubilizer with said water-soluble polymer, wherein said matrix further comprises said solubilizer.

17. (Newly added) The process of Claim 16 wherein said solubilizer comprises polyethylene glycol.

18. (Newly added) The process of Claim 11 wherein said excipient is selected from the group consisting of starch, sucrose, talc and mixtures thereof.

19. (Newly added) The process of Claim 11 wherein the mixing occurs at a temperature at which the polymer melts and the pharmaceutical agent remains crystalline.

20. (Newly added) The process of Claim 11 wherein said pharmaceutical agent is selected from the group consisting of acetohexamide,